Start Time: 08:00 January 1, 0000 8:51 AM ET
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Q2 2023 Earnings Conference Call
August 01, 2023, 08:00 AM ET
Company Participants
David Meeker - Chairman, President, and CEO
Jennifer Chien - EVP, Head of North America
Yann Mazabraud - EVP, Head of International
Hunter Smith - CFO
David Connolly - Executive Director, IR and Corporate Communications
Conference Call Participants
Divya Rao - TD Cowen
Derek Archila - Wells Fargo
Corinne Jenkins - Goldman Sachs
Dae Gon Ha - Stifel
Michael Higgins - Ladenburg Thalmann
Joseph Stringer - Needham & Company
Michael Riad - Morgan Stanley
Operator
Good day and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Dave Connolly, Executive Director of Investor Relations and Corporate Communications. Please go ahead.
David Connolly
Thank you, Bella. I'm Dave Connolly, here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section on the Investors page of our Web site at ir.rhythmtx.com. This morning, we issued a press release that provides our second quarter 2023 financial results and a business update, which is available on our Web site.
As listed here on Slide 2 is our agenda. Here with me today in Boston are David Meeker, Chair, Chief Executive Officer, and President of Rhythm Pharmaceuticals; Jennifer Chien, Executive Vice President, Head of North America; Hunter Smith, our Chief Financial Officer; and Yann Mazabraud, Executive Vice President, Head of International is on the line joining us from Europe.
And on Slide 3, I’ll remind you that this call contains remarks concerning future expectations, plans, and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly reports on file with the SEC.
In addition, any forward-looking statements represents our views only as of today and should not be relied upon as presenting our views as of any subsequent date. We specifically disclaim any obligation to update such statements.
With that, I'll turn the call over to David Meeker, who will begin on Slide 5.